|Bid||10.22 x 3000|
|Ask||10.39 x 1000|
|Day's Range||10.20 - 10.69|
|52 Week Range||6.31 - 15.59|
|Beta (3Y Monthly)||2.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.30|
CymaBay Therapeutics, Inc. (CBAY), today announced the early completion of enrollment in a Phase 2b dose-ranging, paired liver biopsy study of seladelpar for the treatment of nonalcoholic steatohepatitis (NASH). The company expects to report 12-week topline results on changes in liver fat and key biochemical parameters in the second quarter.
CymaBay Therapeutics, Inc. (CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar for the treatment of early stage primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adult patients with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Seladelpar is an orally administered, potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently being evaluated in a global, Phase 3 registration study, ENHANCE, for patients with PBC.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching CymaBay Therapeutics, Inc. (NASDAQ:CBAY) mightRead More...
NEWARK, Calif., Jan. 02, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Details the CEO buys this past week from the following companies: Allogene Therapeutics, Conagra Brands, Texas Capital Bancshares, Fastenal and CymaBay Therapeutics
Are you looking for a post-summer portfolio boost? Look no further. Investment firm Oppenheimer has released a bullish report highlighting its latest Top Stock Picks for September 2018. "These are the most timely stocks in the opinion of our research analysts" stated the firm. "Each analyst was asked to contribute the one idea they considered to outperform over the next 12 months, based on their view of the company's fundamentals in the context of current market conditions." The report lists 30 top stocks. But here I focus on the seven stocks that truly stand out from the crowd. I used TipRanks' market data to cherry-pick the report's best stocks. These are the the stocks which boast a "strong buy" consensus rating from the Street. This is based on all the ratings each stock has received over the last three months. That way we have the added reassurance of knowing that these stocks score big across the board.Let's take a closer look at these hot shots now: SEE ALSO FROM KIPLINGER: 12 Top Stock Picks to Shield Your Portfolio